{"product_id":"vorbio-marketing-mix","title":"Vor Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to a Strategic 4Ps Breakdown\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how Vor’s Product, Price, Place, and Promotion decisions combine to create market impact with our concise 4P’s preview—then unlock the full, editable Marketing Mix Analysis for an expert deep dive. Save hours with presentation-ready insights, data-backed examples, and strategic recommendations you can apply immediately. Purchase the complete report to benchmark Vor’s approach and adapt proven tactics for your business or coursework.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEngineered eHSCs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEngineered eHSCs are clinical-stage hematopoietic stem cells (Vor Biopharma) engineered for resistance to targeted post-transplant therapies, exemplified by CD33 antigen editing to permit concurrent anti-CD33 agents while preserving stemness. Core value: enabling deeper, safer eradication of residual disease after transplant. Targeting ~50,000 allogeneic transplants\/year (EBMT ~2022) turns transplant into a combinable therapeutic platform.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTherapy Shielding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTherapy Shielding enables use of otherwise myeloablative or off-target agents post-transplant, expanding the therapeutic window for antibodies, ADCs and bispecifics and enabling sequential or maintenance regimens. Post-transplant relapse remains a major issue (≈20–50% across indications), so the aim is lower relapse with preserved hematopoiesis. The global oncology biologics market exceeded $150B in 2024, highlighting commercial upside.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLead Indications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInitial launch targets AML and MDS patients undergoing allogeneic HSCT, focusing on high-risk molecular subsets (FLT3 mutations in ~25–30% of AML, TP53 ~5–10%) and the ~30–40% of patients who remain MRD-positive after therapy. Label expansion plans include other myeloid malignancies such as MDS and CMML. Pediatric and relapsed\/refractory cohorts to follow after proof-of-concept; ~9,000 allogeneic transplants reported annually in the US. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGMP Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVor's GMP manufacturing uses closed, scalable cell-processing with release criteria targeting viability \u0026gt;70%, editing fidelity \u0026gt;95% and engraftment potential aligned to clinical benchmarks. Cryopreservation strategy supports scheduling flexibility and multi-week storage windows. Chain-of-identity and chain-of-custody are fully digitized; CMC roadmap aligns with FDA and EMA expectations for global filings.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eviability: \u0026gt;70%\u003c\/li\u003e\n\u003cli\u003eediting fidelity: \u0026gt;95%\u003c\/li\u003e\n\u003cli\u003edigitized COI\/COC\u003c\/li\u003e\n\u003cli\u003eCMC aligned to FDA\/EMA\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompanion Ecosystem\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePlatform designed to pair with partner therapeutics targeting edited antigens, enabling co-development with pharma to validate combination protocols; FDA issued 2024 guidance clarifying co-development expectations for companion diagnostics and therapeutics. Companion diagnostics confirm antigen status and edit integrity at point-of-care; robust IP portfolio covers editing constructs and specified agent uses.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCo-development: aligns with FDA 2024 co-development guidance\u003c\/li\u003e\n\u003cli\u003eDiagnostics: confirm antigen status\/edit integrity\u003c\/li\u003e\n\u003cli\u003eIP: claims on constructs + agent-specific use\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEngineered eHSCs enable post-transplant \u003cstrong\u003eCD33\u003c\/strong\u003e editing to cut relapse and unlock targeted therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEngineered eHSCs enable post-transplant combination therapy by antigen editing (eg CD33) to preserve stemness while permitting targeted agents, targeting ~50,000 allogeneic transplants\/year (EBMT) and ~9,000 US\/year. Aim: reduce 20–50% relapse rates; oncology biologics market \u0026gt;$150B (2024). Initial focus AML\/MDS (FLT3 25–30%, MRD+ 30–40%); release specs viability \u0026gt;70%, editing fidelity \u0026gt;95%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal allogeneic transplants\u003c\/td\u003e\n\u003ctd\u003e~50,000\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS allogeneic transplants\u003c\/td\u003e\n\u003ctd\u003e~9,000\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePost-transplant relapse\u003c\/td\u003e\n\u003ctd\u003e≈20–50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology biologics market\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$150B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eViability\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEditing fidelity\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;95%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFLT3 in AML\u003c\/td\u003e\n\u003ctd\u003e25–30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMRD+ post-therapy\u003c\/td\u003e\n\u003ctd\u003e30–40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a company-specific, professional deep dive into Vor’s Product, Price, Place, and Promotion strategies, using real brand practices and competitive context to ground recommendations; ideal for managers, consultants, and marketers who need a clean, republishable breakdown for reports, workshops, or benchmarking.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses the Vor 4P's into a concise, plug-and-play one-pager that clarifies product, price, place and promotion to relieve stakeholder confusion and speed alignment for presentations, workshops, or rapid decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTransplant Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePrimary delivery occurs through accredited hematopoietic stem cell transplant centers accredited by FACT and JACIE, leveraging embedded workflows with transplant coordinators and cell therapy pharmacists to manage patient selection, apheresis, processing and infusion.\u003c\/p\u003e\n\u003cp\u003eOnsite training for GMP processing and bedside infusion is standard practice, with post-infusion monitoring integrated into center EMRs such as Epic and Cerner to enable real-time toxicity tracking and documentation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVor's clinical network targets multi-center trials across 71 NCI-designated centers to seed adoption, prioritizing sites with \u0026gt;100 annual AML\/MDS cases to accelerate enrollment; standardized SOPs cut procedural variability and speed activation. Data capture uses eSource and registries (CIBMTR, \u0026gt;500,000 records) to ensure robust real-world outcomes and regulatory-grade evidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCryologistics combine +2 to +8°C chains for biologics and vapor‑phase liquid nitrogen storage at about −150°C for cell therapies to preserve viability. Vor maintains two or more redundant GMP sites and partnerships with multiple CDMOs to secure capacity and resilience. End‑to‑end real‑time GPS and temperature telemetry track apheresis through product return. Contingency plans mandate expedited release testing workflows targeting ≤72 hours and defined re‑manufacture protocols.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeographic Phasing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePhase 1 targets U.S. priority with select EU centers of excellence (Germany, UK) to capture ~45% of the 2024 global cell therapy market; Phase 2 expands to broader EU plus select APAC markets (Japan, South Korea, Australia) with mature transplant ecosystems. QA\/QC will be localized to FDA, EMA and PMDA standards and reimbursement access (HTA\/payer alignment) secured pre-launch.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePhase1: US + select EU centers\u003c\/li\u003e\n\u003cli\u003ePhase2: broader EU + APAC (JP, KR, AU)\u003c\/li\u003e\n\u003cli\u003eRegulatory: localize QA\/QC to FDA\/EMA\/PMDA\u003c\/li\u003e\n\u003cli\u003eCommercial: reimbursement aligned before launch\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Orchestration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDigital Orchestration centralizes provider portal case submission, scheduling and lot status tracking, supporting rapid workflows and driving reported reductions in manual admin times of up to 60% in automated centers (2024 pilots). Integrated dashboards consolidate logistics and adverse event reporting, improving detection and response cadence. APIs to payer portals accelerate prior authorization, while embedded educational assets lift care-team guideline adherence.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProvider portal: case submission, scheduling, lot status\u003c\/li\u003e\n\u003cli\u003eDashboards: logistics + adverse event reporting\u003c\/li\u003e\n\u003cli\u003eAPIs: payer portal authorizations, up to 60% faster\u003c\/li\u003e\n\u003cli\u003eEmbedded education: increases care-team guideline adherence\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e\n\u003cstrong\u003e71\u003c\/strong\u003e centers, 500k+ records, ≤72h release with embedded coordinators\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVor distributes via 71 FACT\/JACIE centers targeting sites with \u0026gt;100 AML\/MDS cases, using embedded coordinators\/pharmacists and ERP-integrated monitoring; two+ redundant GMP\/CDMO sites and vapor‑phase LN2 storage preserve chain integrity. eSource\/CIBMTR (\u0026gt;500,000 records) supports regulatory evidence; 2024 pilots show up to 60% admin time reduction and ≤72h expedited release targets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNCI centers targeted\u003c\/td\u003e\n\u003ctd\u003e71\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSite volume threshold\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;100 AML\/MDS\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCIBMTR records\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;500,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdmin time reduction (pilot)\u003c\/td\u003e\n\u003ctd\u003eup to 60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRelease testing target\u003c\/td\u003e\n\u003ctd\u003e≤72 hours\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 market reach goal\u003c\/td\u003e\n\u003ctd\u003e~45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You Preview Is What You Download\u003c\/span\u003e\u003cbr\u003eVor 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Vor 4P's Marketing Mix Analysis you'll receive instantly after purchase—no surprises. This editable, comprehensive document is the final version, ready to use and download immediately. You're viewing exactly what you'll own upon checkout, so buy with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":55675277476217,"sku":"vorbio-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/vorbio-marketing-mix.png?v=1755805333","url":"https:\/\/portersfiveforce.com\/products\/vorbio-marketing-mix","provider":"Porter's Five Forces","version":"1.0","type":"link"}